Analystreport

Tcr2 Therapeutics Inc (NASDAQ: TCRR) had its "buy" rating re-affirmed by analysts at HC Wainwright.

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report